- Report
- February 2024
- 70 Pages
France
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Spain
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Iran
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Russia
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Australia
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
China
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
Japan
From €4544EUR$4,750USD£3,864GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4544EUR$4,750USD£3,864GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4544EUR$4,750USD£3,864GBP
- Report
- October 2022
- 70 Pages
Africa
From €4544EUR$4,750USD£3,864GBP
- Report
- August 2020
- 150 Pages
Global
From €4066EUR$4,250USD£3,457GBP
- Report
- October 2019
- 125 Pages
Canada
From €4544EUR$4,750USD£3,864GBP
- Report
- April 2020
- 119 Pages
Global
From €3502EUR$3,660USD£2,977GBP
- Report
- August 2023
- 51 Pages
South Korea
From €574EUR$600USD£488GBP
- Report
- August 2023
- 51 Pages
India
From €574EUR$600USD£488GBP
Alpha Glucosidase Inhibitors are a class of drugs used to treat Endocrine and Metabolic Disorders. These drugs work by inhibiting the enzyme alpha-glucosidase, which is responsible for breaking down carbohydrates in the small intestine. This helps to reduce the amount of glucose absorbed into the bloodstream, which can help to control blood sugar levels. Alpha Glucosidase Inhibitors are commonly used to treat type 2 diabetes, as well as other conditions such as polycystic ovary syndrome and gestational diabetes.
Alpha Glucosidase Inhibitors are available in both oral and injectable forms. Common side effects of these drugs include abdominal pain, nausea, and diarrhea. Long-term use of these drugs can also lead to an increased risk of hypoglycemia.
Some companies that produce Alpha Glucosidase Inhibitors include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more